Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. reports news on its dermatology therapeutics business, including commercialization of YCANTH (VP-102) for molluscum contagiosum and development of cantharidin-based therapy for common warts. Company updates also cover financial results, corporate presentations, commercial leadership and international commercialization activity.
Verrica’s pipeline news centers on VP-315 (ruxotemitide), an oncolytic peptide licensed for dermatologic oncology indications. Recurring disclosures include clinical data presentations in basal cell carcinoma, development plans for non-melanoma skin cancers and collaboration activity tied to YCANTH and its dermatology portfolio.
Verrica Pharmaceuticals (Nasdaq: VRCA) appointed Chris Chapman as Chief Commercial Officer effective Feb 12, 2026. Chapman brings over 25 years of commercial pharmaceutical experience and leadership across dermatology, including roles at Dermavant, Organon, Galderma, and Pfizer.
Management expects Chapman to expand U.S. commercial capabilities for YCANTH, support the global Phase 3 program for common warts, and advance development of VP-315 for basal cell carcinoma.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced the launch of YCANTH in Japan by partner Torii Pharmaceutical for the treatment of molluscum contagiosum. YCANTH received MHLW approval based on positive Phase 3 topline results showing statistically significant complete clearance versus placebo.
Verrica retains global rights outside Japan; a multi‑year manufacturing transfer to Torii is planned, with interim transfer pricing and future royalties tied to transferred components and Torii net sales.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced the first patient was dosed in December 2025 in its global Phase 3 program evaluating YCANTH (VP-102) for common warts.
The Phase 3 start follows positive Phase 2 COVE-1 topline results where 51% (18 of 35) of subjects in Cohort 2 achieved complete clearance at Day 84; adverse events were primarily local cutaneous reactions with no SAEs observed. Verrica retains global rights to YCANTH outside Japan.
Torii will split Phase 3 costs 50/50, funding the first $40 million (about 90% of the current trial budget); Verrica recently completed a $50 million financing and repaid its OrbiMed debt facility. Verrica cites a U.S. prevalence of ~22 million patients and no FDA‑approved therapies for common warts.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced a private placement PIPE financing raising approximately $50 million in gross proceeds, expected to close on or about November 25, 2025. Verrica said it will use about $35.0 million of net proceeds to fully repay its credit agreement with OrbiMed and the remainder for working capital, extending its expected cash runway into mid-2027.
The financing is anchored by Caligan Partners and PBM Capital, includes sales of common stock, pre-funded warrants and accompanying Series C warrants, and gives Caligan the right to designate a board member.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported $14.3M revenue in Q3 2025, driven by $3.6M YCANTH product sales and $10.7M license/collaboration revenue (including a $10M Torii milestone for Japan approval).
The company said dispensed YCANTH applicators rose to 37,642 YTD (a 120% increase vs prior year) and Q3 dispensings were 14,093 (+4.9% sequential). FDA and EMA provided positive regulatory feedback for VP-315 Phase 3 and YCANTH MAA pathways; Torii will fund most global Phase 3 wart trial costs. Q3 net loss was $0.3M and cash totaled $21.1M as of September 30, 2025.
Verrica Pharmaceuticals (Nasdaq: VRCA) presented Phase 2 translational and clinical data for VP-315 at SITC (Nov 5–9, 2025). In Part 2, 82 subjects (92 tumors) received intratumoral VP-315; an exploratory immune analysis in 22 subjects (24 tumors) showed increased CD3+, CD4+, CD8+ T-cell and CD20+ B-cell densities and reduced immunosuppressive cells 12–14 weeks post-treatment.
Clinical outcomes reported: 97% objective response rate (post-hoc), 51% complete histologic clearance, 86% overall tumor-size reduction, and no treatment-related serious adverse events. Company reported End-of-Phase 2 FDA agreement and is preparing a pivotal Phase 3 program.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that the CHMP of the European Medicines Agency provided positive scientific advice supporting a Marketing Authorization Application (MAA) for YCANTH as a treatment for molluscum contagiosum.
The CHMP concluded that the primary and supportive secondary endpoints from previously completed Phase 3 studies in the U.S. and Japan are adequate and no additional Phase 3 studies are required. Verrica is initiating activities to support an MAA submission that could be filed as early as Q4 2026. The feedback covers adult and pediatric patients aged 2 years and older, and addresses study design, clinical safety data, and nonclinical/literature adequacy.
Verrica Pharmaceuticals (Nasdaq: VRCA) will present new Phase 2 data on VP-315, an oncolytic peptide for basal cell carcinoma (BCC), at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, November 5–9, 2025, in National Harbor, Maryland.
The company will deliver an oral presentation (Abstract 529) on November 6, 2025 during Concurrent Session 205b with a 12:46–12:54 p.m. ET presentation slot exploring local immune activation in the tumor microenvironment 12 weeks after VP-315. A companion poster with the same exploratory analysis will also be presented. The abstract will be posted on the SITC website on or about November 4, 2025 at 9:00 a.m. ET.
Verrica Pharmaceuticals (NASDAQ:VRCA) announced that its development partner, Torii Pharmaceutical, has received approval from Japan's Ministry of Health for YCANTH® (TO-208) to treat Molluscum Contagiosum. This approval triggers a $10 million milestone payment to Verrica, strengthening its balance sheet with non-dilutive capital.
The approval follows positive Phase 3 trial results in Japan, where YCANTH demonstrated statistically significant efficacy in achieving complete clearance of molluscum lesions compared to placebo. Verrica maintains global rights to YCANTH outside Japan and plans to initiate a global Phase 3 program for common warts treatment by the end of 2025.
Verrica Pharmaceuticals (NASDAQ:VRCA), a dermatology therapeutics company, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York City. The company's President and CEO, Jayson Rieger, PhD, MBA, will present on Monday, September 8, 2025, at 9:30 am ET.
Investors can access the presentation through a live webcast available on Verrica's website, with a replay available for 90 days following the event.